Biodel to file VIAject insulin for diabetes
This article was originally published in Scrip
Executive Summary
Biodel has announced plans to submit an NDA to the US FDA for its lead product, an ultra-rapid-acting injectable human insulin, VIAject, to treat type 1 and type 2 diabetes, in the second half of this year.